Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content
Authors:
- 1 June 1993
- journal article
- clinical trial
- Published by Wiley in Liver International
- Vol. 13 (3) , 156-162
Abstract
ABSTRACT— In order to clarify debated issues of the medical treatment of ascites in cirrhosis – the usefulness of a low sodium diet and washout period preceding diuretic administration, maximal dosage of antimineralocorticoid to be reached before the addition of a loop diuretic, identifications of factors influencing treatment efficacy – 115 hospitalized patients with non‐azotemic cirrhosis and ascites were recruited and randomized to receive a diet providing either 40 or 120 mmol of sodium daily. After a washout period from the outpatient diuretic regimen for 7 days (Step 1), increasing dosages of K‐canrenoate (200 mg/day every 4th day up to 600 mg) were administered to patients not undergoing spontaneous diuresis (Step 2). Upon the failure of Step 2, K‐canrenoate (400 mg/day) and furosemide at increasing dosage (25–50–100 mg every other day) were given (Step 3). Nine percent of patients underwent spontaneous diuresis, and 77% developed a negative sodium balance by the end of Step 2 (69% with a dosage of K‐canrenoate ≤400 mg/day) and 93% by the end of Step 3. Two patients were withdrawn from the protocol due to diuretic side‐effects. Univariate analysis showed that the type of diet did not influence the response to treatment. The washout period led to a significant increase in endogenous creatinine clearance; natremia significantly rose in hyponatremic patients. Multivariate analysis showed that creatinine clearance and plasma aldosterone were independent predictive factors of the response to treatment. The use of low‐sodium diet did not enhance the efficacy of the medical treatment of non‐azotemic cirrhotic ascites and a washout period from diuretics improved renal function and natremia. Antimineralocorticoids up to 400 mg/day were successful in over 2/3 of cases and the improvement in efficacy obtained by a further increase in dose was small. Endogenous creatinine clearance and plasma aldosterone significantly influenced treatment efficacy. The therapeutic regimen employed in this study was highly effective and had a very low incidence of side effects.Keywords
This publication has 11 references indexed in Scilit:
- A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patientsHepatology, 1991
- Renal Functional Impairment and Sodium Retention in Liver CirrhosisDigestion, 1989
- Pathophysiology of ascites and functional renal failure in cirrhosisJournal of Hepatology, 1988
- Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascitesGastroenterology, 1987
- Rapid diuresis in patients with ascites from chronic liver disease: The importance of peripheral edemaGastroenterology, 1986
- Salt or no salt in the treatment of cirrhotic ascites: a randomised study.Gut, 1986
- Renal function impairment induced by change in posture in patients with cirrhosis and ascites.Gut, 1985
- Importance of Plasma Aldosterone Concentration on the Natriuretic Effect of Spironolactone in Patients with Liver Cirrhosis and AscitesDigestion, 1985
- Advantages of treatment of ascites without sodium restriction and without complete removal of excess fluid.Gut, 1978
- Clinical types and drug therapy of renal impairment in cirrhosisPostgraduate Medical Journal, 1975